Cart
sales@molnova.com
Fezakinumab
CAS No. 1007106-86-6
Fezakinumab( —— )
Catalog No. M36710 CAS No. 1007106-86-6
Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 426 | In Stock |
|
| 10MG | 660 | In Stock |
|
| 25MG | 1007 | In Stock |
|
| 50MG | 1330 | In Stock |
|
| 100MG | 1795 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFezakinumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionFezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.
-
DescriptionFezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorInterleukin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1007106-86-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patrick M Brunner, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol?
molnova catalog
related products
-
ACTH 4-11
ACTH (4-11) is a peptide fragment of adrenocorticotropic hormone, a peptide hormone found in the brain that is involved in the biological stress response.
-
Monatepil maleate
Monatepil maleate (AJ-2615 maleate) is an orally active Ca2+-channel and α1-adrenoceptor antagonist and non-competitive heparanoyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with antihypertensive activity.
-
MRT-2359
MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.
